About Krishna Reddy, MD, MS

Dr. Reddy is a pulmonary and critical care physician at Massachusetts General Hospital and an Assistant Professor of Medicine at Harvard Medical School.

Dr. Reddy earned an MD from Harvard Medical School and a Master of Science in Epidemiology degree from the Harvard T.H. Chan School of Public Health. He was a Fulbright Scholar in Spain and a Fogarty Scholar in Peru.

Departments, Centers, & Programs:

Treats:

Languages:

Locations

Mass General Pulmonary & Critical Care
55 Fruit St.
Boston, MA 02114
Phone: 617-726-1721

Medical Education

  • MD, Harvard Medical School*
  • Residency, Massachusetts General Hospital

American Board Certifications

  • Critical Care Medicine, American Board of Internal Medicine
  • Pulmonary Disease, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Reddy’s research interests include tobacco, HIV, and tuberculosis, both individually and in combination. He applies methods of simulation modeling, epidemiology, and cost-effectiveness analysis to study clinical and economic outcomes in the US and in other countries. The goal of his research is to provide evidence- and model-based approaches to clinical decision-making and public health policy. Dr. Reddy is a faculty investigator in the Medical Practice Evaluation Center (www.massgeneral.org/medicine/mpec) and the Tobacco Research and Treatment Center (www.massgeneral.org/medicine/trtc), both at MGH.

Dr. Reddy’s work has been reported by NBC News, Reuters, and WBUR/National Public Radio. He has been invited to present his work as a consultant to the World Health Organization. His research is supported by the National Institutes of Health.

Publications

  • Reddy KP, Denkinger CM, Broger T, McCann NC, Gupta-Wright A, Kerkhoff AD, Pei PP, Shebl FM, Fielding KL, Nicol MP, Horsburgh CR, Meintjes G, Freedberg KA, Wood R, Walensky RP. Cost-effectiveness of a novel lipoarabinomannan test for tuberculosis in patients with HIV. Clin Infect Dis 2020:ciaa1698.

    Reddy KP, Bulteel AJB, Levy DE, Torola P, Hyle EP, Hou T, Osher B, Yu L, Shebl FM, Paltiel AD, Freedberg KA, Weinstein MC, Rigotti NA, Walensky RP. Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population. BMJ Open 2020;10(5):e032579.

    Reddy KP, Gupta-Wright A, Fielding KL, Costantini S, Zheng A, Corbett EL, Yu L, van Oosterhout JJ, Resch SC, Wilson DP, Horsburgh CR, Wood R, Alufandika-Moyo M, Peters JA, Freedberg KA, Lawn SD, Walensky RP. Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. Lancet Glob Health 2019;7:e200.

    Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA, Paltiel AD, Losina E, Weinstein MC, Freedberg KA, Walensky RP. Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States. JAMA Intern Med 2017;177:1613.

    Reddy KP, Parker RA, Losina E, Baggett TP, Paltiel AD, Rigotti NA, Weinstein MC, Freedberg KA, Walensky RP. Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study. J Infect Dis 2016;214:1672.

Reviews: Comments and Ratings